세계 에리스로포이에틴 제제 시장 : 규모 조사 및 예측 - 유형별, 제품별, 용도별, 지역별 분석(2023-2030년)

Global Erythropoietin Drugs Market is valued at approximately USD 6.87 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% during the forecast period 2023-2030. Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone that stimulates the production of red blood cells in the bone marrow, a process known as erythropoiesis. Initially developed to address anemic conditions arising from End-Stage Renal Disease (ESRD) and related treatments such as dialysis, EPO drugs have expanded their applications. Following successful Post-abbreviated New Drug Application (ANDA) approvals, EPO drugs have been increasingly sanctioned for managing chemotherapy-induced anemia. The market growth is driven by key factors such as the rising incidence of chronic diseases and the rising number of CKD cases.

The growth can be attributed to the rising incidence of chronic diseases such as cancer, end-stage renal diseases, HIV, and neurological diseases. As per Statista, the prevalence of individuals experiencing at least two chronic diseases in Italy varied between 2010 and 2022, exhibiting an overall upward trend. In 2018, the peak was observed, with over 12.9 million people affected by at least two chronic diseases. By 2022, approximately 12.6 million Italians were grappling with at least two chronic diseases.. Furthermore, By the year 2050, it is anticipated that this number will surge to approximately 171 million. The prevalence of individuals with chronic conditions in the United States has been on a gradual rise since 1995. This data depicts the count of individuals with chronic medical conditions in the United States spanning from 1995 to 2020, along with projections for 2025 and 2050. However, the launch of alternative drugs and increased demand for EPO Side effects stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Erythropoietin Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the overall erythropoietin drugs market in terms of the revenue share of XX% in 2022. The regional market is anticipated to significantly benefit from local organizations that are actively engaged in advancing the development and use of erythropoietin drugs. Along with this, Asia Pacific is expected to witness fastest growth with CAGR XX% over the forecast period. The growth of the region is attributed to the presence of key players in the market and strategic initiatives undertaken by them to develop and commercialize new erythropoietin drug products to treat anemia patients.

Major market player included in this report are:

• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• LG Chem
• Biocon
• Sun Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd

Recent Developments in the Market:

• In November 2022, Dong-A ST forged a strategic partnership with Polifarma regarding the DA-3880 NESP biosimilar. This collaboration granted Polifarma the right to commercialize and advance the development of DA-3880 in the markets of Brazil, Mexico, and Turkey.
• In September 2021, Wanbang Biopharma obtained approval from the National Medical Products Administration (NMPA) for Yi Bao (Human Erythropoietin Injection). This approval signifies its intended use in addressing chemotherapy-related anemia in individuals with non-myeloid malignancies.

Global Erythropoietin Drugs Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, Application, Type, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Erythropoietin
• Darbepoetin-alfa

By Type:

• Biologics
• Biosimilars

By Application:

• Cancer
• Renal Diseases
• Neurology
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Erythropoietin Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Erythropoietin Drugs Market, by Type, 2020-2030 (USD Billion)
  • 1.2.3. Erythropoietin Drugs Market, by Product, 2020-2030 (USD Billion)
  • 1.2.4. Erythropoietin Drugs Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Erythropoietin Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Erythropoietin Drugs Market Dynamics

• 3.1. Erythropoietin Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidence of chronic diseases
    • 3.1.1.2. Rising number of CKD cases
  • 3.1.2. Market Challenges
    • 3.1.2.1. Launch of alternative drugs
    • 3.1.2.2. Increased demand for EPO Side effects
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rise in trends of commercialization for erythropoietin biosimilars
    • 3.1.3.2. Increase in level of awareness regarding benefits of EPO therapeutics

Chapter 4. Global Erythropoietin Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Erythropoietin Drugs Market, by Type

• 5.1. Market Snapshot
• 5.2. Global Erythropoietin Drugs Market by Type, Performance - Potential Analysis
• 5.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
• 5.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 5.4.1. Biologics
  • 5.4.2. Biosimilars

Chapter 6. Global Erythropoietin Drugs Market, by Product

• 6.1. Market Snapshot
• 6.2. Global Erythropoietin Drugs Market by Product, Performance - Potential Analysis
• 6.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 6.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 6.4.1. Erythropoietin
  • 6.4.2. Darbepoetin-alfa

Chapter 7. Global Erythropoietin Drugs Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Erythropoietin Drugs Market by Application, Performance - Potential Analysis
• 7.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 7.4.1. Cancer
  • 7.4.2. Renal Diseases
  • 7.4.3. Neurology
  • 7.4.4. Others

Chapter 8. Global Erythropoietin Drugs Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Erythropoietin Drugs Market, Regional Market Snapshot
• 8.4. North America Erythropoietin Drugs Market
  • 8.4.1. U.S. Erythropoietin Drugs Market
    • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Erythropoietin Drugs Market
• 8.5. Europe Erythropoietin Drugs Market Snapshot
  • 8.5.1. U.K. Erythropoietin Drugs Market
  • 8.5.2. Germany Erythropoietin Drugs Market
  • 8.5.3. France Erythropoietin Drugs Market
  • 8.5.4. Spain Erythropoietin Drugs Market
  • 8.5.5. Italy Erythropoietin Drugs Market
  • 8.5.6. Rest of Europe Erythropoietin Drugs Market
• 8.6. Asia-Pacific Erythropoietin Drugs Market Snapshot
  • 8.6.1. China Erythropoietin Drugs Market
  • 8.6.2. India Erythropoietin Drugs Market
  • 8.6.3. Japan Erythropoietin Drugs Market
  • 8.6.4. Australia Erythropoietin Drugs Market
  • 8.6.5. South Korea Erythropoietin Drugs Market
  • 8.6.6. Rest of Asia Pacific Erythropoietin Drugs Market
• 8.7. Latin America Erythropoietin Drugs Market Snapshot
  • 8.7.1. Brazil Erythropoietin Drugs Market
  • 8.7.2. Mexico Erythropoietin Drugs Market
• 8.8. Middle East & Africa Erythropoietin Drugs Market
  • 8.8.1. Saudi Arabia Erythropoietin Drugs Market
  • 8.8.2. South Africa Erythropoietin Drugs Market
  • 8.8.3. Rest of Middle East & Africa Erythropoietin Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Teva Pharmaceutical Industries Ltd.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Johnson & Johnson Services, Inc.
  • 9.3.3. Intas Pharmaceuticals Ltd.
  • 9.3.4. Novartis AG
  • 9.3.5. Amgen, Inc.
  • 9.3.6. F. Hoffmann-La Roche Ltd.
  • 9.3.7. LG Chem
  • 9.3.8. Biocon
  • 9.3.9. Sun Pharmaceutical Industries Ltd
  • 9.3.10. Dr. Reddy's Laboratories Ltd

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption